FDA Grants Fast Track Designation to Bayer's Investigational Compound Alpharadin™
- Details
- Category: Bayer
Bayer HealthCare announced today that its investigational compound Alpharadin™ (radium-223 chloride), which is exclusively licensed from Algeta ASA, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of castration-resistant (hormone refractory) prostate cancer in patients with bone metastases.
GSK takes minority stake in new spin out Autifony Therapeutics
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc announced that its wholly-owned subsidiary Glaxo Group Limited (GSK) will receive a 25.4% minority equity stake, representing a £1,250,000 investment, in Autifony Therapeutics Limited,
Pfizer Announces EMA Acceptance of Regulatory Submissions
- Details
- Category: Pfizer
Pfizer Inc. announced that the European Medicines Agency (EMA) has accepted Pfizer's regulatory submissions for review of two investigational compounds
Boehringer Ingelheim licenses ProBioGen's novel GlymaxX® technology
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and ProBioGen AG have signed a non-exclusive Licensing Agreement regarding ProBioGen's GlymaxX® technology. Boehringer Ingelheim's Contract Manufacturing Business will apply the technology to enhance ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of antibodies.
FDA approves Zelboraf and companion diagnostic for BRAF mutation-positive metastatic melanoma
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as determined by an FDA-approved test.
Nycomed reports double-digit growth across emerging markets in second quarter 2011
- Details
- Category: Nycomed
Nycomed today announced results for the second quarter of 2011, achieving double digit growth across emerging markets. Good progress was made in Key Products, particularly in the respiratory area.
GSK and Impax announce positive topline results of ASCEND-PD Phase III study
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) and Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL) announced top-line results of the ASCEND-PD Phase III clinical study of IPX066 versus carbidopa-levodopa plus entacapone (CLE), in patients with advanced Parkinson's disease (PD).
More Pharma News ...
- Pfizer Wins Viagra Patent Trial
- Bayer to support WHO and Stop Tuberculosis Partnership in fighting tuberculosis
- Merck and Serum Institute Announce Collaboration
- Results of ROCKET AF Study of Bayer’s Xarelto® (Rivaroxaban)
- Lundbeck's first half report 2011
- Lilly Announces Review of Data on Long-Term Raloxifene Treatment
- Many Americans May Have Low Vitamin D Levels